Conservatism, Consumer Choice, and the Food and Drug Administration during the Reagan Era: A Prescription for Scandal
In the last quarter of the 20th century, politicians in Washington, as well as interest groups, regulatory policy makers, and drug industry leaders were forced to confront the hot-button issue of pharmaceutical regulation. The struggle always centered on product innovation, consumer protection, and choice in the free market. As the American economy stuttered in the late 1970s, the stakes were extremely high for the powerful drug industry and the American public. At the center of this drama was the Food and Drug Administration, which was censured from both the left and right of the political spectrum for being too strict and too lenient in the application of its regulatory powers.
Lucas Richert explores the FDA, drugs, and politics in the context of the watershed Reagan era, a period when the rhetoric of limited government, reduced regulation, and enhanced cooperation between businesses and U.S. regulatory agencies was on the ascent. As he investigates the controversies surrounding Laetrile, Reye’s Syndrome, Oraflex, patient package inserts, diet pills, and HIV/AIDS drugs, Richert argues that the practical application of conservative economic principles to the American drug industry was A Prescription for Scandal.
What people are saying - Write a review
We haven't found any reviews in the usual places.
2 Disenchantment and Drug Regulation during the Seventies
3 President Carter and the FDA
Reagan and the FDA in 19801982
5 The Continuing Evolution of the FDA 19831984
6 Reagans Leadership Health Activism and the HIVAIDS Crisis
Other editions - View all
Conservatism, Consumer Choice, and the Food and Drug Administration During ...
No preview available - 2014
97th Congress According actions agency’s AIDS drugs American Arthur Hull Hayes bill budget Bureau of Drugs bureaucracy Bush Carter clinical trials congressional consumer activist consumer protection critical Democratic deregulation Drug Administration drug applications drug approval process drug companies drug industry drug lag Drug Regulation drug review process economic effective election enforcement FDA commissioner FDA drug FDA officials FDA Oral History FDA Today FDA’s federal Food and Drug Frank Young George H.W. Bush Goyan groups Hatch-Waxman Hilts HIV/AIDS Ibid increased industry’s Institute Interview investigation Jimmy Carter John Dingell Kennedy Kessler Laetrile legislation Medicine ment National Office Oral History Collection patients Paul Hile percent pharmaceutical industry political President Reagan presidential Reagan administration Reagan administration’s regulatory agencies regulatory reform Republican Research Ronald Reagan safety scandal Schweiker Senate significant staff Subcommittee tion treatment IND U.S. Congress U.S. pharmaceutical University Press Washington York